Peter Clark, MA, MD, FRCP: A Payer Perspective

First International Summit on Interventional Pharmacoeconomics

Amit Sanyal, MD: A Clinician’s Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Collyar: What's In It for Patients?

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Nov

Today In Oncology

Peter Clark, MA, MD, FRCP: A Payer Perspective

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Collyar: What's In It for Patients?

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Could Opportunistic Salpingectomy Prevent Ovarian Cancer in Postreproductive Women

Large AI Breast Cancer Screening Trial Increases Detection Rate

Addition of Durvalumab to BCG After TURBT for BCG-Naive, High-Risk NMIBC

Geriatric Assessment–Guided Approach to Treatment Intensity in Older Adults With Acute Myeloid Leukemia

Reducing the Barriers to Receiving CAR T-Cell Therapy for Patients With Hematologic Malignancies